Inhibition of erythropoietin‐producing hepatoma receptor B4 (EphB4) signalling suppresses the vascularisation and growth of endometriotic lesions
article
OA: bronze
CC0
⤵ 5 in-corpus citations
Abstract
BACKGROUND AND PURPOSE: The development of endometriotic lesions is crucially dependent on the formation of new blood vessels. In the present study, we analysed whether this process is regulated by erythropoietin-producing hepatoma receptor B4 (EphB4) signalling. EXPERIMENTAL APPROACH: We first assessed the anti-angiogenic action of the EphB4 inhibitor NVP-BHG712 in different in vitro angiogenesis assays. Then, endometriotic lesions were surgically induced in the dorsal skinfold chamber and peritoneal cavity of NVP-BHG712- or vehicle-treated BALB/c mice. This allowed to study the effect of EphB4 inhibition on their vascularisation and growth by means of intravital fluorescence microscopy, high-resolution ultrasound imaging, histology and immunohistochemistry. KEY RESULTS: Non-cytotoxic doses of NVP-BHG712 suppressed the migration, tube formation and sprouting activity of both human dermal microvascular endothelial cells (HDMEC) and mouse aortic rings. Accordingly, we also detected a lower blood vessel density in NVP-BHG712-treated endometriotic lesions. This was associated with a reduced lesion growth due to a significantly lower number of proliferating stromal cells when compared to vehicle-treated controls. CONCLUSIONS AND IMPLICATIONS: Inhibition of EphB4 signalling suppresses the vascularisation and growth of endometriotic lesions. Hence, EphB4 represents a promising pharmacological target for the treatment of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (51)
- A GFP endometriosis model reveals important morphological characteristics of the angiogenic process that govern benign and malignant diseases. via openalex
- Anti-angiogenic treatment strategies for the therapy of endometriosis via openalex
- Basic mechanisms of vascularization in endometriosis and their clinical implications via openalex
- Blocking of Stromal Cell-Derived Factor-1 Reduces Neoangiogenesis in Human Endometriosis Lesions in a Mouse Model via openalex
- Circulating Endothelial Progenitor Cells Are Up-Regulated in a Mouse Model of Endometriosis via openalex
- Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor- by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions via openalex
- Comprehensive study of angiogenic factors in women with endometriosis compared to women without endometriosis via openalex
- Endometriosis via openalex
- Estrogen Stimulates Homing of Endothelial Progenitor Cells to Endometriotic Lesions via openalex
- High-Resolution Ultrasound Imaging via openalex
- Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis via openalex
- In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy via openalex
- Notch signaling controls sprouting angiogenesis of endometriotic lesions via openalex
- Pathogenesis and pathophysiology of endometriosis via openalex
- Pathogenesis of Endometriosis: The Role of Peritoneal Fluid via openalex
- Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity via openalex
- The social and psychological impact of endometriosis on women's lives: a critical narrative review via openalex
- doi:10.1007/s10456-010-9183-z via openalex
- doi:10.1111/jcmm.13105 via openalex
- doi:10.22203/ecm.v028a20 via openalex
- doi:10.18632/oncotarget.6676 via openalex
- doi:10.1016/j.semcancer.2017.10.002 via openalex
- doi:10.1242/jcs.00426 via openalex
- doi:10.1093/humupd/dmm006 via openalex
- doi:10.1093/humrep/des095 via openalex
- doi:10.1111/bph.14751 via openalex
- doi:10.22203/ecm.v032a13 via openalex
- doi:10.3109/10799893.2013.795971 via openalex
- doi:10.1182/blood-2006-05-023341 via openalex
- doi:10.1074/jbc.m207221200 via openalex
- doi:10.1111/bph.14112 via openalex
- doi:10.1038/jcbfm.2010.220 via openalex
- doi:10.1111/bph.12955 via openalex
- doi:10.1016/j.yexmp.2016.03.011 via openalex
- doi:10.1093/nar/gkx1121 via openalex
- doi:10.2353/ajpath.2008.061244 via openalex
- doi:10.1111/bph.14153 via openalex
- doi:10.1016/s1097-2765(00)80342-1 via openalex
- doi:10.1242/dev.129.6.1397 via openalex
- doi:10.22203/ecm.v022a12 via openalex
- doi:10.1161/01.atv.0000096655.56262.56 via openalex
- doi:10.1097/sla.0b013e31818fa52f via openalex
- doi:10.1182/blood-2011-02-338426 via openalex
- doi:10.1007/s10456-013-9366-5 via openalex
- doi:10.1111/j.1476-5381.2010.00872.x via openalex
- doi:10.20344/amp.5244 via openalex
- doi:10.1159/000025710 via openalex
- doi:10.1007/s10456-016-9514-9 via openalex
- doi:10.1016/j.ajpath.2010.11.037 via openalex
- doi:10.1016/j.ajpath.2017.10.013 via openalex
- doi:10.1016/j.fertnstert.2013.07.1967 via openalex
Cited by (5)
- The "double-edged sword" effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of endometriosis (EMS) 2025
- EXPRESSION OF THE TYROSINE KINASE RECEPTOR (EPHA1) IN THE EUTOPIC AND ECTOPIC ENDOMETRIUM OF PATIENTS WITH DEEP INFILTRATIVE ENDOMETRIOSIS USE OF MODERN DIGITAL TECHNOLOGIES 2022
- Targeting sphingosine kinase‐1 with the low MW inhibitor SKI‐5C suppresses the development of endometriotic lesions in mice 2021
- Differences in growth and vascularization of ectopic menstrual and non-menstrual endometrial tissue in mouse models of endometriosis 2021
- THE INFLUENCE OF ENDOMETRIOID HETEROTOPIAS ON THE RED BLOOD PARAMETERS 2020
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-05-11T03:23:52.597003+00:00
- pubmed
- last seen: 2026-05-13T22:22:11.167363+00:00
License: CC0
· commercial use OK